Davita Inc vs PepsiCo, Inc. — how do they compare? Davita Inc trades at $178.01 (market cap $11.29B), while PepsiCo, Inc. trades at $126.5 (market cap $174.89B). The key difference: PepsiCo, Inc. is far larger — about 15.5× Davita Inc's market cap, and PepsiCo, Inc. pays a 4.61% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and PepsiCo, Inc. for 107 Days on average.
| DVA | PEP | |
|---|---|---|
Market Cap | $11.29B | $174.89B |
Volume | 582,204 | 23,968,864 |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $170.44 |
52-Week Low | $103.87 | $123.64 |
Typical Hold Time | 113 Days | 107 Days |
Enterprise Value | $24.01B | $215.61B |
Dividend Yield | — | 4.61% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
PepsiCo (PEP) trades at $123.64, down 1.65% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates for four consecutive quarters, with Q3 2026 EPS of $2.34 exceeding expectations. Revenue growth remains steady at $93.93B for 2025, though net income margin declined to 8.77%. Recent news highlights price adjustments for snack products and sponsorship changes.
PepsiCo presents a mixed investment case with strong profitability metrics (ROE 51.59%) and analyst consensus price target of $146.77 (18.7% upside), but faces headwinds from consumer price sensitivity and technical weakness. The company's cash flow stability and dividend payments provide defensive characteristics, though execution risks in North American markets warrant monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →